Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
About the study
Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Subjects who have received P-BCMA-101 and completed or discontinued early from a Poseida sponsored treatment protocol.
- Subject has provided informed consent.
EXCLUSION CRITERIA
Exclusion Criteria:
None
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Multiple Myeloma
Age (in years)
18+
Phase
Phase 1
Participants needed
100
Est. Completion Date
Nov 30, 2032
Treatment type
Interventional
Sponsor
Poseida Therapeutics, Inc.
ClinicalTrials.gov identifier
NCT03741127
Study number
P-BCMA-101-002
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?